PDCD1 and neoplasm: Insufficient tumour immunogenicity, dysfunction of MHC, presence of other inhibitory receptors, IFN-γ signal resistance and an immunosuppressive microenvironment play a key role in the development of resistance to anti-PD-1/PD-L1 therapy (Fig. 1) [16].